DK1718756T3 - Botulinumtoksinscreeningassays - Google Patents

Botulinumtoksinscreeningassays

Info

Publication number
DK1718756T3
DK1718756T3 DK05724048.3T DK05724048T DK1718756T3 DK 1718756 T3 DK1718756 T3 DK 1718756T3 DK 05724048 T DK05724048 T DK 05724048T DK 1718756 T3 DK1718756 T3 DK 1718756T3
Authority
DK
Denmark
Prior art keywords
methods
bont
activity
botulinumtoksinscreeningassays
fgfr3
Prior art date
Application number
DK05724048.3T
Other languages
English (en)
Inventor
Ester Fernandez-Salas
Patton E Gary
Kei Roger Aoki
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK1718756T3 publication Critical patent/DK1718756T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
DK05724048.3T 2004-02-24 2005-02-23 Botulinumtoksinscreeningassays DK1718756T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54759104P 2004-02-24 2004-02-24
PCT/US2005/006421 WO2005082096A2 (en) 2004-02-24 2005-02-23 Botulinum toxin screening assays

Publications (1)

Publication Number Publication Date
DK1718756T3 true DK1718756T3 (da) 2012-02-27

Family

ID=34910920

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05724048.3T DK1718756T3 (da) 2004-02-24 2005-02-23 Botulinumtoksinscreeningassays

Country Status (9)

Country Link
US (3) US7598027B2 (da)
EP (1) EP1718756B1 (da)
JP (1) JP4970057B2 (da)
AT (1) ATE533853T1 (da)
AU (2) AU2005216547B2 (da)
CA (1) CA2558758C (da)
DK (1) DK1718756T3 (da)
ES (1) ES2374822T3 (da)
WO (1) WO2005082096A2 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080064054A1 (en) * 2001-08-28 2008-03-13 Ester Fernandez-Salas Fluorescence resonance energy transfer (fret) assays for clostridial toxin activity
US7208285B2 (en) 2001-08-28 2007-04-24 Allergan, Inc. Fret protease assays for botulinum serotype A/E toxins
US7374896B2 (en) * 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
US8022172B2 (en) * 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US7332567B2 (en) * 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US7183066B2 (en) * 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
WO2005082096A2 (en) * 2004-02-24 2005-09-09 Allergan, Inc. Botulinum toxin screening assays
US8497081B2 (en) * 2004-02-24 2013-07-30 Allergan, Inc. Botulinum toxin screening assays
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US20080274480A1 (en) * 2004-08-04 2008-11-06 Allergan, Inc. Botulinum Toxin Type a Immunoresistant Assay
AU2006225116B2 (en) 2005-03-15 2012-04-19 Allergan, Inc. Modified Clostridial toxins with altered targeting capabilities for Clostridial toxin target cells
WO2007047342A1 (en) * 2005-10-12 2007-04-26 Allergan, Inc. Assays of molecular or subcellular interactivity using depolarization after resonance energy transfer (daret)
JP2009543556A (ja) * 2006-07-11 2009-12-10 アラーガン、インコーポレイテッド 増強した転位置能力および増強したターゲティング活性を有する改変クロストリジウム毒素
WO2009042165A2 (en) * 2007-09-25 2009-04-02 Thomas Jefferson University Mutant botulinum neurotoxin serotype a polypeptide and uses thereof
CN102937653B (zh) 2008-03-14 2015-09-09 阿勒根公司 基于免疫的血清型a肉毒杆菌毒素活性测定
KR101604515B1 (ko) * 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
EP2313435A4 (en) * 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
RU2535003C2 (ru) 2008-12-10 2014-12-10 Аллерган, Инк. Фармацевтические композиции токсина клостридий
WO2010085473A1 (en) 2009-01-20 2010-07-29 Trustees Of Tufts College Methods for the delivery of toxins or enzymatically active portions thereof
ES2689703T3 (es) * 2009-03-13 2018-11-15 Allergan, Inc. Células útiles para ensayos de actividad de serotipo A de toxina botulínica basados en la respuesta inmunológica
CN102422158B (zh) 2009-03-13 2015-04-08 阿勒根公司 基于免疫的重靶向内肽酶活性测定
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
CN103958747B (zh) * 2011-09-29 2017-03-01 塞尔斯纳普有限责任公司 用于产毒性测试的组合物和方法
US10451621B2 (en) 2011-12-31 2019-10-22 Allergan, Inc. Highly sensitive cell-based assay to detect the presence of active botulinum neurotoxin serotype-A
WO2013170206A1 (en) * 2012-05-11 2013-11-14 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Research & Material Command Toxin detection using stem cell derived neurons
NZ702310A (en) 2012-05-30 2016-08-26 Harvard College Engineered botulinum neurotoxin
US8962340B2 (en) 2012-12-03 2015-02-24 Src, Inc. Real-time assay for the detection of botulinum toxin
WO2014111744A1 (en) * 2013-01-16 2014-07-24 INSERM (Institut National de la Santé et de la Recherche Médicale) A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
LT3270162T (lt) * 2013-08-09 2020-09-10 Biomadison, Inc. Padidinto jautrumo botulino toksino tyrimas
JP6630717B2 (ja) 2014-07-07 2020-01-15 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 組織試料における切断ｓｎａｐ２５の検出方法
ES2895853T3 (es) 2015-03-26 2022-02-22 Harvard College Neurotoxina botulínica modificada
EP4122955A1 (en) 2016-07-07 2023-01-25 Pfizer Inc. Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof
EP3504226A1 (en) 2016-08-24 2019-07-03 President and Fellows of Harvard College Engineered botulinum neurotoxin
IL308091A (en) 2016-09-13 2023-12-01 Allergan Inc Stabilized Clostridium toxin preparations without protein
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
SG11202005757SA (en) 2017-12-20 2020-07-29 Allergan Inc Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation
KR101940500B1 (ko) * 2018-11-29 2019-01-21 주식회사 에이비바이오 보툴리눔 독소 활성을 결정하기 위한 세포주 및 이를 이용한 활성 결정 방법
LT3660509T (lt) 2018-11-29 2022-05-10 Hugel Inc. Ląstelių panaudojimu paremtas būdas botulino toksino aktyvumui nustatyti
JP2020015733A (ja) * 2019-08-19 2020-01-30 アンセルムＩｎｓｅｒｍ 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド
AR123306A1 (es) 2020-08-21 2022-11-16 Genzyme Corp Anticuerpos fgfr3 y métodos de uso

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750365A (en) * 1993-05-28 1998-05-12 The Ohio State University Research Foundation Isolated nucleic acid encoding a newt acidic fibroblast growth factor (AFGF)
US5962637A (en) * 1994-06-03 1999-10-05 Microbiological Research Authority Toxin assay
US5731161A (en) * 1995-04-24 1998-03-24 Allergan, Inc. Botulinum toxin antibody detection assay
US5965699A (en) * 1996-11-06 1999-10-12 The United States Of America As Represented By The Secretary Of The Army Assay for the proteolytic activity of serotype a from clostridium botulinum
US7923216B2 (en) * 1997-08-14 2011-04-12 Institut Pasteur In vivo modulation of neuronal transport
US7923015B2 (en) * 1997-08-14 2011-04-12 Institut Pasteur Methods for direct visualization of active synapses
US6794128B2 (en) * 1998-04-24 2004-09-21 The Regents Of The University Of California Methods of selecting internalizing antibodies
IL128380A0 (en) * 1999-02-04 2000-01-31 Yeda Res & Dev A method of screening for agonists and antagonists of FGFR
NZ516504A (en) * 1999-09-15 2003-09-26 Janssen Pharmaceutica Nv Nicotinic acetylcholine receptor
US20030219462A1 (en) * 2000-07-21 2003-11-27 Allergan Sales, Inc Clostridial neurotoxin compositions and modified clostridial neurotoxins
US6913877B1 (en) * 2000-09-11 2005-07-05 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Methods for detecting bioactive compounds
IL138529A0 (en) * 2000-09-18 2003-09-17 Yeda Res & Dev High level expression of heterologous proteins
CA2447357A1 (en) * 2001-05-22 2002-11-28 Gene Logic, Inc. Molecular toxicology modeling
WO2002102854A2 (en) 2001-06-20 2002-12-27 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20080064054A1 (en) * 2001-08-28 2008-03-13 Ester Fernandez-Salas Fluorescence resonance energy transfer (fret) assays for clostridial toxin activity
US7208285B2 (en) * 2001-08-28 2007-04-24 Allergan, Inc. Fret protease assays for botulinum serotype A/E toxins
US20070118934A1 (en) * 2001-10-26 2007-05-24 Planet Biotechnology, Inc. Chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax
WO2003083046A2 (en) * 2002-03-08 2003-10-09 Curagen Corporation Novel proteins and nucleic acids encoding same
IL149562A0 (en) * 2002-05-09 2002-11-10 Prochon Ltd Fgf variants and methods for use thereof
WO2003101484A1 (en) * 2002-05-31 2003-12-11 Thomas Jefferson University Compositions and methods for transepithelial molecular transport
US7183066B2 (en) * 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
US20070135514A1 (en) * 2002-12-03 2007-06-14 Berkley Lynch Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
US7090985B2 (en) * 2002-12-03 2006-08-15 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
WO2004076634A2 (en) * 2003-02-24 2004-09-10 Ira Sanders Cell membrane translocation of regulated snare inhibitors , compositions therefor, and methods for treatment of disease
IL156495A0 (en) 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
EP2050736A1 (en) * 2003-12-02 2009-04-22 UCB Pharma, S.A. Imidazole derivatives, processes for preparing them and their uses
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
JP4656836B2 (ja) * 2003-12-19 2011-03-23 パナソニック株式会社 同期クロック生成装置及び同期クロック生成方法
WO2005082096A2 (en) * 2004-02-24 2005-09-09 Allergan, Inc. Botulinum toxin screening assays
WO2006012309A1 (en) * 2004-06-25 2006-02-02 Cold Spring Harbor Laboratory Inducible inactivation of synaptic transmission
CA2604039C (en) * 2005-04-05 2014-09-16 Allergan, Inc. Lipophilic dye-based fret assays for clostridial toxin activity
EP1985276A1 (en) * 2007-04-26 2008-10-29 Merz Pharma GmbH & Co. KGaA Treatment of movement disorders by a combined use of a chemodenervating agent and automated movement therapy

Also Published As

Publication number Publication date
JP4970057B2 (ja) 2012-07-04
WO2005082096A2 (en) 2005-09-09
ES2374822T3 (es) 2012-02-22
WO2005082096A3 (en) 2006-06-22
US20080003240A1 (en) 2008-01-03
AU2009202136B2 (en) 2011-12-22
EP1718756B1 (en) 2011-11-16
ATE533853T1 (de) 2011-12-15
AU2005216547A1 (en) 2005-09-09
US20080182799A1 (en) 2008-07-31
US7645570B2 (en) 2010-01-12
CA2558758A1 (en) 2005-09-09
CA2558758C (en) 2015-06-23
EP1718756A4 (en) 2008-06-04
US20090317839A1 (en) 2009-12-24
US7598027B2 (en) 2009-10-06
AU2009202136A1 (en) 2009-06-18
US8257914B2 (en) 2012-09-04
EP1718756A2 (en) 2006-11-08
JP2007526770A (ja) 2007-09-20
AU2005216547B2 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
DK1718756T3 (da) Botulinumtoksinscreeningassays
NO20210557A1 (no) Modifiserte antigen-bindende molekyler med endret celle-signaliseringsaktivitet
ATE476659T1 (de) Sensor für mehrere analyte
DK1745144T3 (da) Analysefremgangsmåde til opsporing af lægemidler på grundlag af in vitro-differentierede celler
ATE514755T1 (de) Fluoreszenzfarbstoffe zur verwendung bei der glukoseerfassung
ATE446509T1 (de) Serumfreie expansion von zellen in kultur
DE602006013653D1 (de) System zum nachweis und zur analyse der ausbreitung biologischer abfallprodukte in unterwäsche
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
DE602005017876D1 (de) Brennstoffzellensystem und steuerverfahren dafür
NO20091064L (no) Antistoffer mot IL-17A
DE602005016800D1 (de) Hif-prolylhydroxylase-aktivitätstest
DK1896571T3 (da) Materialer og fremgangsmåder, der vedrører cellebaserede behandlinger
ATE471147T1 (de) Verwendung von (r)-(halogenbenzyloxy)-benzylamino-propanamiden als natrium- und/oder calciumkanal- selektive modulatoren
DE602006013921D1 (de) Brennstoffzelle und Brennstoffzellenanalage
DE602005015559D1 (de) Pharmakodynamische tests mit durchflusszytometrie
EP2535050A3 (en) Compositions and methods for detection of lysosomal storage disease
WO2007026355A3 (en) Modulators of cell migration and methods of identifying same
DE602005008325D1 (de) Quantifizierung von Enzymaktivität mittels planarer Wellenleiter
CY1112090T1 (el) Μεθοδος για ανιχνευση βιολογικων οργανισμων με χρηση σκεδασης raman
WO2012024546A3 (en) Incorporation of health measurments in analysis and interpretation of functional biological response data
ATE553386T1 (de) Bluttypisierung
DE602005015270D1 (de) Druckplattenmaterial und Druckverfahren, das dieses Material verwendet
DE602005017817D1 (de) Alterungsbiomarker
ATE489628T1 (de) Galk1s als modifikatoren des pten/akt-wegs
BRPI0607663A2 (pt) processo para a caracterização da atividade de transativação e transrepressão de ligantes do receptor glicocorticóide em células imunológicas primárias